These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 22410254)

  • 21. Recurrent Kawasaki disease.
    Balasubramanian S; Ganesh R
    Indian J Pediatr; 2009 Aug; 76(8):848-9. PubMed ID: 19475343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High neutrophil : lymphocyte ratio is associated with refractory Kawasaki disease.
    Cho HJ; Bak SY; Kim SY; Yoo R; Baek HS; Yang S; Hwang IT; Ban JE
    Pediatr Int; 2017 Jun; 59(6):669-674. PubMed ID: 28097746
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Immunoglobulin in suspected Kawasaki disease].
    García Soblechero E; Gómez Santos E; Domínguez Quintero ML; González Vila L
    An Pediatr (Barc); 2010 Sep; 73(3):151-2. PubMed ID: 20605119
    [No Abstract]   [Full Text] [Related]  

  • 24. Prediction of intravenous immunoglobulin resistance in patients with Kawasaki disease according to the duration of illness prior to treatment.
    Ha KS; Lee J; Lee KC
    Eur J Pediatr; 2020 Feb; 179(2):257-264. PubMed ID: 31713683
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lack of CD4⁺CD25⁺FOXP3⁺ regulatory T cells is associated with resistance to intravenous immunoglobulin therapy in patients with Kawasaki disease.
    Hirabayashi Y; Takahashi Y; Xu Y; Akane K; Villalobos IB; Okuno Y; Hasegawa S; Muramatsu H; Hama A; Kato T; Kojima S
    Eur J Pediatr; 2013 Jun; 172(6):833-7. PubMed ID: 23340699
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IL-1B polymorphism in association with initial intravenous immunoglobulin treatment failure in Taiwanese children with Kawasaki disease.
    Weng KP; Hsieh KS; Ho TY; Huang SH; Lai CR; Chiu YT; Huang SC; Lin CC; Hwang YT; Ger LP
    Circ J; 2010 Mar; 74(3):544-51. PubMed ID: 20081319
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Japanese Kawasaki Disease Scoring Systems: Are they Applicable to the Iranian Population?
    Edraki MR; Mohammadi H; Mehdizadegan N; Ghorashi M; Amoozgar H; Borzouee M; Ajami G; Keshavarz K; Dehghani E; Bahrami R
    Arch Iran Med; 2020 Jan; 23(1):31-36. PubMed ID: 31910632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. External validation of a scoring system to predict resistance to intravenous immunoglobulin.
    Kobayashi T; Inoue Y; Tamura K; Morikawa A; Kobayashi T
    J Pediatr; 2007 Apr; 150(4):e37; author reply e38. PubMed ID: 17382098
    [No Abstract]   [Full Text] [Related]  

  • 29. Immunoglobulin failure and retreatment in Kawasaki disease.
    Durongpisitkul K; Soongswang J; Laohaprasitiporn D; Nana A; Prachuabmoh C; Kangkagate C
    Pediatr Cardiol; 2003; 24(2):145-8. PubMed ID: 12457253
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of efficacy of six prediction models for intravenous immunoglobulin resistance in Kawasaki disease.
    Qian W; Tang Y; Yan W; Sun L; Lv H
    Ital J Pediatr; 2018 Mar; 44(1):33. PubMed ID: 29523168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Should infliximab be used as an adjuvant to IVIG in the treatment of children with Kawasaki disease who are at high risk for resistance to conventional therapy?
    Davies S; Gold-von Simson G
    Pediatr Cardiol; 2013 Oct; 34(7):1756. PubMed ID: 23771701
    [No Abstract]   [Full Text] [Related]  

  • 32. Adjunctive therapies in Kawasaki disease.
    Tremoulet AH
    Int J Rheum Dis; 2018 Jan; 21(1):76-79. PubMed ID: 29076637
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Arthritis in Kawasaki disease after responding to intravenous immunoglobulin treatment.
    Lee KY; Oh JH; Han JW; Lee JS; Lee BC
    Eur J Pediatr; 2005 Jul; 164(7):451-2. PubMed ID: 15782294
    [No Abstract]   [Full Text] [Related]  

  • 34. Serum albumin level predicts initial intravenous immunoglobulin treatment failure in Kawasaki disease.
    Kuo HC; Liang CD; Wang CL; Yu HR; Hwang KP; Yang KD
    Acta Paediatr; 2010 Oct; 99(10):1578-83. PubMed ID: 20491705
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Methylprednisolone pulse therapy in Kawasaki disease].
    Miura M; Matsuoka M; Kohno K; Ohki H; Yoshiba S
    Nihon Rinsho; 2008 Feb; 66(2):338-42. PubMed ID: 18265457
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of longitudinal and radial left ventricular functions on 2-D and 3-D echocardiography before and after intravenous immunoglobulin in acute Kawasaki disease.
    Hashimoto I; Saitou Y; Sakata N; Shibata K
    Pediatr Int; 2017 Dec; 59(12):1229-1235. PubMed ID: 28892213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-classical Kawasaki disease in a 2 month old infant.
    Hartmann I; Weiss K; Bistritzer T; Baram S; Goldman M
    Isr Med Assoc J; 2006 Aug; 8(8):581-2. PubMed ID: 16958253
    [No Abstract]   [Full Text] [Related]  

  • 38. [Risk stratification and prediction of resistance to intravenous immunoglobulin in Kawasaki disease].
    Kobayashi T; Inoue Y; Morikawa A
    Nihon Rinsho; 2008 Feb; 66(2):332-7. PubMed ID: 18260333
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of the predictive validity of the combination of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio and other risk scoring systems for intravenous immunoglobulin (ivig)-resistance in Kawasaki disease.
    Takeshita S; Kanai T; Kawamura Y; Yoshida Y; Nonoyama S
    PLoS One; 2017; 12(5):e0176957. PubMed ID: 28542183
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Verification of risk scores to predict i.v. immunoglobulin resistance in incomplete Kawasaki disease.
    Kanamitsu K; Kakimoto H; Shimada A; Nakata Y; Ochi H; Watanabe H; Iwasaki Y; Tokorodani C; Kanazawa A; Maruyama H; Miyazawa M; Nishiuchi R; Kikkawa K
    Pediatr Int; 2016 Feb; 58(2):146-51. PubMed ID: 26190225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.